论文部分内容阅读
不稳定斑块破裂、血栓形成是急性冠状动脉综合征的主要病理基础。对于急性冠状动脉综合征患者,尤其是准备接受经皮冠状动脉介入术的患者,许多大规模临床试验已经证实阿司匹林和氯吡格雷联合用药,不但能降低高危心血管危险因素患者的心血管事件发生率,而且可以显著减少经皮冠状动脉介入术围手术期缺血性并发症的发生。然而,临床观察发现,接受标准化阿司匹林和氯吡格雷治疗的患者中大约有1%~45%仍发生心血管事件[1]。这一现象表明,不同个体对抗血小板药物治疗反应性不同,因此,抗血小板药物治疗“抵抗”和“低反应性”成为目前临床研究的热点。
Unstable plaque rupture, thrombosis is the main pathological basis of acute coronary syndrome. In patients with acute coronary syndromes, and in particular those who are undergoing percutaneous coronary intervention, many large-scale clinical trials have demonstrated that aspirin and clopidogrel in combination can reduce the risk of cardiovascular events in high-risk cardiovascular risk patients Rate, but also can significantly reduce percutaneous coronary intervention perioperative ischemic complications. However, clinical observations indicate that approximately 1% -45% of patients treated with standardized aspirin and clopidogrel continue to experience cardiovascular events [1]. This phenomenon indicates that different individuals have different reactivity to antiplatelet drugs. Therefore, antiplatelet drug therapy has become the hot point of current clinical research.